The Cardiovascular Risk Profile is a tool to measure risk of heart disease and diabetes. It provides extensive evaluation of biomarkers of abnormal lipoprotein metabolism, vascular inflammation, coagulation, glomerular filtration and glucose homeostasis, as well as the status of magnesium, iron and key antioxidants. Assessing cardiometabolic function is the first step in treating it.
Arterial damage is associated with the infiltration of white cells into vessel walls and inflammation, which increases blood levels of two acute phase proteins, C-reactive protein and ferritin. Although not specific to CVD, analysis of these two proteins is valuable in assessing CVD risk. Total and LDL cholesterol, total triglycerides and HDL cholesterol have traditionally been measured to gauge CVD risk.
However, recent research indicates that more focused biomarkers can provide even greater insight. For example, oxidized LDL and small dense LDL have been found to be higher in CVD patients and correlated with the severity of CVD. In addition, levels of apolipoproteins A1 and B, specific protein constituents of HDL and LDL, are also strong indicators of risk.
Because oxidative stress is a component of CVD, the Comprehensive Cardiovascular Risk Profile measures plasma levels of three primary antioxidants: coenzyme Q10 and alpha- and gamma- tocopherol. The test also looks for elevated serum homocysteine, which has long been established as a risk factor. Finally, long-term blood glucose homeostasis and glomerular filtration assessments round out the battery of risk factors analyzed.